United Therapeutics Corporation (UTHR)
United Therapeutics: A Unique Business With High Margins And Expansion Potential
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion.
Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for United Therapeutics (UTHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
UTHR or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UTHR vs. STVN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy
UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across major product lines, with Tyvaso, Orenitram, and Unituxin all posting significant YoY increases. My numbers project a 40% growth in earnings power for the business over the coming 2-3 years.
